Congenital Cytomegalovirus: Efficacy of Antiviral Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 22, 2013

Primary Completion Date

May 17, 2018

Study Completion Date

May 17, 2018

Conditions
Congenital Cytomegalovirus InfectionSensorineural Hearing Loss
Interventions
DRUG

Valganciclovir

Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.

Trial Locations (1)

2300 RC

Department Medical Microbiology, Leiden

All Listed Sponsors
collaborator

Stichting Nuts Ohra

OTHER

collaborator

Leiden University Medical Center

OTHER

lead

Dr. Ann C.T.M. Vossen

OTHER

NCT02005822 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment | Biotech Hunter | Biotech Hunter